Remove Article Remove Dosage Remove Immunization
article thumbnail

Implications of RFK Jr.’s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry

PharmaTech

s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. ACIP plays a foundational role in shaping immunization policy in the US.

article thumbnail

FDA Mandates Major Opioid Label Revisions to Highlight Long-Term Risks

Pharmacy Times

Suggestions for providers featured in the guidelines include determining if opioids should take place, selecting appropriate dosages, determining prescription length and follow-up, and assessing and reducing risks of misuse, overdose, and opioid use disorder.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

Acalabrutinib plus bendamustine and rituximab may become new standard care for untreated MCL. Cancer Therapy Advisor. June 21, 2024. Accessed March 16, 2025.

article thumbnail

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma

Pharmacy Times

The study aimed to evaluate both safety and preliminary efficacy outcomes, with a specific focus on hematologic toxicity, pharmacokinetics, and immune system effects. Flow cytometry data indicated no significant increases in immune checkpoint markers typically associated with T-cell exhaustion.

article thumbnail

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL

Pharmacy Times

2 Len enhances immune response and promotes antibody-dependent cellular cytotoxicity, whereas R targets CD20-expressing B cells. 4,5 This multimodal immune engagement likely contributes to the response observed even in patients with low CD30 expression.

article thumbnail

FDA Mandates Safety Alterations to Opioid Pain Medication Labels

PharmExec

New labels will include study summaries, improved dosage warnings, and information on overdose reversal agents to enhance patient and healthcare professional awareness. The FDA mandates randomized clinical trials to assess long-term opioid use benefits and risks, ensuring timely and efficient completion.

article thumbnail

3 of the year’s most notable FDA nods

PharmaVoice

Published June 27, 2025 Meagan Parrish Lead Editor post share post print email license Justin Sullivan via Getty Images Listen to the article 7 min This audio is auto-generated. Other PrEP regimens on the market require daily oral dosages or shots every few months, but the latest version is only administered twice a year.